Researchers detected tiny tumor DNA fragments in blood, potentially enabling more sensitive cancer screening methods in the future.
The study identified circulating tumor DNA (ctDNA) fragments as small as 50 base pairs, improving detection sensitivity for early-stage cancers. This approach could lead to non-invasive blood tests for various cancers, including lung and breast. Scientists used next-generation sequencing to analyze blood samples from patients. The breakthrough was reported in recent scientific publications.
Key Findings
- Fragments smaller than previously detectable.
- Higher accuracy in identifying mutations.
Further trials are planned to validate clinical use.